Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get trading ideas, historical data, advanced options screeners, more. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Allogene Therapeutics Inc (ALLO)
Allogene Therapeutics Inc (ALLO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 718,150
  • Shares Outstanding, K 144,497
  • Annual Sales, $ 240 K
  • Annual Income, $ -332,630 K
  • 60-Month Beta 0.81
  • Price/Sales 3,038.60
  • Price/Cash Flow N/A
  • Price/Book 1.11
Trade ALLO with:

Options Overview Details

View History
  • Implied Volatility 106.21% ( +106.21%)
  • Historical Volatility 40.75%
  • IV Percentile 95%
  • IV Rank 78.61%
  • IV High 121.44% on 12/20/22
  • IV Low 50.25% on 03/13/23
  • Put/Call Vol Ratio 0.00
  • Today's Volume 0
  • Volume Avg (30-Day) 20
  • Put/Call OI Ratio 2.83
  • Today's Open Interest 5,943
  • Open Int (30-Day) 5,815

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/23
See More
  • Average Estimate -0.63
  • Number of Estimates 11
  • High Estimate -0.58
  • Low Estimate -0.72
  • Prior Year -0.56
  • Growth Rate Est. (year over year) -12.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.83 +3.72%
on 03/30/23
7.14 -29.83%
on 03/01/23
-1.34 (-21.10%)
since 02/28/23
3-Month
4.83 +3.72%
on 03/30/23
8.44 -40.64%
on 01/27/23
-0.77 (-13.32%)
since 12/28/22
52-Week
4.83 +3.72%
on 03/30/23
17.49 -71.36%
on 08/12/22
-4.52 (-47.43%)
since 03/28/22

Most Recent Stories

More News
Here's Why Allogene Therapeutics (ALLO) is Poised for a Turnaround After Losing -17.44% in 4 Weeks

The heavy selling pressure might have exhausted for Allogene Therapeutics (ALLO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street...

ALLO : 5.06 (+1.81%)
Why Is Allogene Therapeutics (ALLO) Down 19.4% Since Last Earnings Report?

Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

ALLO : 5.06 (+1.81%)
ALNY : 198.14 (+1.55%)
Aridis (ARDS) Stock Up as Cystic Fibrosis Study Meets Goals

Aridis Pharmaceuticals (ADRS) meets primary and secondary endpoints in a phase IIa study on AR-501 for treating cystic fibrosis.

CRSP : 44.81 (+1.47%)
KALA : 14.58 (-0.11%)
ARDS : 0.3164 (-6.94%)
ALLO : 5.06 (+1.81%)
Reata (RETA) Stock Doubles This Year on Skyclarys FDA Nod

Reata Pharmaceuticals (RETA) stock more than doubles this year, owing to approval for its rare disease drug.

RETA : 90.30 (+0.31%)
CRSP : 44.81 (+1.47%)
KALA : 14.58 (-0.11%)
ALLO : 5.06 (+1.81%)
Roche (RHHBY) Polivy Combo Backed by FDA Advisory Committee

Roche (RHHBY) gets majority votes from the FDA's Advisory Committee for Polivy combination for the treatment of people with previously untreated diffuse large B-cell lymphoma (DLBCL).

RHHBY : 35.7250 (-0.21%)
NVO : 158.69 (+0.38%)
ALLO : 5.06 (+1.81%)
BioNTech (BNTX) to Report Q4 Earnings: What's in the Cards?

BioNTech's (BNTX) fourth-quarter COVID-19 vaccine sales are likely to have declined with the pandemic largely in control. Updates on the company's booster dose authorization status and pipeline will be...

PFE : 40.40 (+0.05%)
ACAD : 19.08 (+2.03%)
ALLO : 5.06 (+1.81%)
BNTX : 123.71 (+0.93%)
Vertex (VRTX) to Begin Clinical Study on Type I Diabetes Drug

Vertex Pharmaceuticals (VRTX) receives FDA clearance to begin clinical development of VX-264, which has the potential to treat type I diabetes.

VRTX : 312.82 (+0.21%)
CRSP : 44.81 (+1.47%)
KALA : 14.58 (-0.11%)
ALLO : 5.06 (+1.81%)
Trevena (TRVN) Initiates Proof-of-Concept for Epilepsy Candidate

Trevena (TRVN) has initiated proof-of-concept study to evaluate TRV045 as a potential treatment for epilepsy and other CNS disorders.

TRVN : 0.7500 (+7.14%)
CRSP : 44.81 (+1.47%)
KALA : 14.58 (-0.11%)
ALLO : 5.06 (+1.81%)
Mesoblast's (MESO) GVHD Drug BLA Gets FDA Priority Tag, Stock Up

Mesoblast (MESO) announces the FDA acceptance for review of the resubmitted biological license application for remestemcel-L for the treatment of children under 12 with steroid-refractory acute graft versus...

INCY : 71.77 (+1.03%)
ADMA : 3.30 (+4.43%)
MESO : 3.21 (+0.94%)
ALLO : 5.06 (+1.81%)
Sanofi (SNY), Regeneron Dupixent sBLA Accepted for FDA Review

Sanofi's (SNY) sBLA seeking label expansion of drug Dupixent for chronic spontaneous urticaria accepted by the FDA

REGN : 816.53 (+0.62%)
SNY : 54.33 (+0.67%)
CRSP : 44.81 (+1.47%)
ALLO : 5.06 (+1.81%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company, primarily focused on the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer.'

See More

Key Turning Points

3rd Resistance Point 5.59
2nd Resistance Point 5.41
1st Resistance Point 5.19
Last Price 5.06
1st Support Level 4.79
2nd Support Level 4.61
3rd Support Level 4.39

See More

52-Week High 17.49
Fibonacci 61.8% 12.65
Fibonacci 50% 11.16
Fibonacci 38.2% 9.67
Last Price 5.06
52-Week Low 4.83

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar